Mooming Pharmaceutical Bar

Mooming Pharmaceutical’s current total market value: 13.27 billion, and circulation market value: 8.060 billion.

Shandong Weiming Biopharmaceutical Co., Ltd. (hereinafter referred to as "Weiming Pharmaceutical" or the "Company") is an A-share public company listed on the Shenzhen Stock Exchange controlled by Weiming Group. The stock abbreviation is: Weiming Famous Medicine, stock code: 002581. Weiming Pharmaceutical will focus on the development of three major systems: drug manufacturing, new drug research and development, and product distribution, and build a complete health product supply system. Through the implementation of the "Hundreds and Trillions Project", Weiming Group will realize one of the three major dreams of Weiming Group - "solve China's health issues”.

1. Shandong Weiming Biopharmaceutical Co., Ltd. was renamed from the "original Zibo Wanchang Technology Co., Ltd." after a major asset reorganization on October 19, 2015. The company owns Weiming Biopharmaceutical Co., Ltd. (Xiamen), Tianjin Weiming Biopharmaceutical Co., Ltd., Beijing Kexing Biological Products Co., Ltd., Shandong Weiming Tianyuan Biotechnology Co., Ltd., Beijing Weiming Xida Biotechnology Co., Ltd., Hefei Peking University Weiming Biopharmaceutical Co., Ltd. and other subsidiaries or production bases.

2. One of the three major dreams of Weiming Group is to "solve China's health problems": to establish a health product supply system through the development of the biomedical industry; to establish a health service system with Chinese characteristics through the development of modern traditional Chinese medicine. ; Establish a life and health management system through the implementation of the GHP plan. Weiming Pharmaceutical will focus on the development of three major systems: drug manufacturing, new drug research and development, and product distribution, and build a complete health product supply system. Through the implementation of the "Hundreds and Trillions Project", Weiming Pharmaceutical will achieve the following goals by 2030: Weiming Pharmaceutical accounts for 10% of the Chinese pharmaceutical market 10% of the total sales, accounting for 50% of the total sales of the biopharmaceutical market, and the market value of the listed company (002581) exceeds one trillion; through the establishment of a new drug highway, Weiming Pharmaceutical will obtain 25 new drug certificates every year; through international enterprises Through restructuring and mergers and acquisitions, Weiming Pharmaceutical has become the largest pharmaceutical enterprise group in the world.

3. In 2015, the company name was changed to "Shandong Weiming Biopharmaceutical Co., Ltd." and the stock abbreviation was changed to "Weiming Pharmaceutical". After the completion of this transaction, Peking University Weiming Bioengineering Group Co., Ltd. holds approximately 26.38% of the company's shares and becomes the company's controlling shareholder